bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend continues. New data from TCT 2014 further reinforces this.

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Roxwood Medical Inc. announced U.S. Food and Drug Administration (FDA) clearance for the U.S. commercialization of its CenterCross Catheter for use in the coronary and peripheral vasculature.

Innovative Cardiovascular Solutions LLC has completed a Class A Unit financing totaling $5 million to fund its Emblok Embolic Protection Catheter. 

Transcatheter Technologies GmbH announced that it has expanded the Trinity technology platform to include a transfemoral version.

As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict what the next big advancements will be in the coming years. Here are my predictions for technologies to watch in the coming year that have the potential to fundamentally change the practice of cardiology:

After watching his father die from heart valve disease, a mechanical engineer used his expertise in fluid dynamics to develop a first-of-its-kind procedure to replace leaking or regurgitating heart valves without touching the heart.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now